| P50 | author | Aziz Zaanan | Q40860284 |
| | David Tougeron | Q57419152 |
| | Benoit Rousseau | Q63372367 |
| P2093 | author name string | Julien Taieb | |
| | Franck Bonnetain | |
| | Pascal Artru | |
| | Thierry Lecomte | |
| | Samy Louafi | |
| | Olivier Bouché | |
| | Christine Rebischung | |
| | Christophe Louvet | |
| | Johann Dreanic | |
| | Nicolas Williet | |
| | Sylvain Manfredi | |
| | Olivier Dubreuil | |
| | May Mabro | |
| | Francesco Savinelli | |
| | Vincent Hautefeuille | |
| | David Sefrioui | |
| | Juliette Palle | |
| | Ludovic Evesque | |
| | Matthieu Sarabi | |
| | Cédric Lecaille | |
| | Emilie Soularue | |
| | Meher Ben Abdelghani | |
| | Astrid Pozet | |
| | Florence Leroy | |
| | Jerome Martin-Babau | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 |
| | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 |
| | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 |
| | Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 |
| | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| | Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer | Q33346628 |
| | Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial | Q33429869 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 |
| | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial | Q34645599 |
| | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv | Q34665199 |
| | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. | Q37109776 |
| | HER2-positive gastric cancer | Q37468290 |
| | Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study | Q37580446 |
| | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 |
| | Involvement of microRNAs in HER2 signaling and trastuzumab treatment. | Q38979308 |
| | Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 |
| | Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 |
| | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 |
| | HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. | Q51541370 |
| | 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). | Q51827397 |
| | Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | Q54291995 |
| | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Q61867571 |
| | Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 |
| P433 | issue | 60 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| | gastric adenocarcinoma | Q18556047 |
| P304 | page(s) | 101383-101393 | |
| P577 | publication date | 2017-09-08 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study | |
| P478 | volume | 8 | |